» Articles » PMID: 25156558

Triggering Through Toll-like Receptor 2 Limits Chronically Stimulated T-helper Type 1 Cells from Undergoing Exhaustion

Overview
Journal J Infect Dis
Date 2014 Aug 27
PMID 25156558
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic infections result in T-cell exhaustion, a state of functional unresponsiveness. To control the infection, it is important to salvage the exhausted T cells. In this study, we delivered signals through Toll-like receptor 2 (TLR-2) to reinvigorate functionality in chronically activated T-helper type 1 (Th1) cells. This process significantly augmented the expression of T-bet, interferon γ, interleukin 2, and the antiapoptotic molecule Bcl-2, whereas it dampened the display of the exhaustion markers programmed death receptor 1 (PD-1) and lymphocyte activation gene 3 (Lag-3). Additionally, TLR-2 signaling bolstered the ability of chronically stimulated Th1 cells to activate B cells. Finally, the results were substantiated by observing reduced lung pathology upon administration of TLR-2 agonist in the chronic infection model of tuberculosis. These data demonstrated the importance of TLR-2 in rescuing chronically activated Th1 cells from undergoing exhaustion. This study will pave a way for targeting TLR-2 in developing therapeutic strategies to treat chronic diseases involving loss of Th1 cell function.

Citing Articles

Harnessing innate immune pathways for therapeutic advancement in cancer.

Hu A, Sun L, Lin H, Liao Y, Yang H, Mao Y Signal Transduct Target Ther. 2024; 9(1):68.

PMID: 38523155 PMC: 10961329. DOI: 10.1038/s41392-024-01765-9.


Immunological factors linked to geographical variation in vaccine responses.

van Dorst M, Pyuza J, Nkurunungi G, Kullaya V, Smits H, Hogendoorn P Nat Rev Immunol. 2023; 24(4):250-263.

PMID: 37770632 DOI: 10.1038/s41577-023-00941-2.


Contribution of T- and B-cell intrinsic toll-like receptors to the adaptive immune response in viral infectious diseases.

Zhang E, Ma Z, Lu M Cell Mol Life Sci. 2022; 79(11):547.

PMID: 36224474 PMC: 9555683. DOI: 10.1007/s00018-022-04582-x.


BCG vaccination strategies against tuberculosis: updates and perspectives.

Qu M, Zhou X, Li H Hum Vaccin Immunother. 2021; 17(12):5284-5295.

PMID: 34856853 PMC: 8903987. DOI: 10.1080/21645515.2021.2007711.


T-cell intrinsic Toll-like receptor signaling: implications for cancer immunotherapy and CAR T-cells.

Nouri Y, Weinkove R, Perret R J Immunother Cancer. 2021; 9(11).

PMID: 34799397 PMC: 8606765. DOI: 10.1136/jitc-2021-003065.